Annovis Bio Announces Long-Term Safety and Efficacy Study of Buntanetap in Parkinson's Disease Patients

Annovis Bio is launching an open-label extension study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in 500 Parkinson's disease patients. The study aims to measure the sustained benefits of buntanetap on motor and cognitive functions, as well as its potential as a disease-modifying treatment. Patients will be treated with buntanetap for 36 months, and enrollment will begin in January 2026.